The recent availability of IL-6 blocking agents in autoimmune diseases [32] may help promote relevant research in this area and there is increasing need to test whether inflammation blockers lessen vascular risk, or otherwise, in a range of differing populations. This evidence concerns the gene IL6 and autoimmune disease.